NASDAQ:MYGN Myriad Genetics (MYGN) Stock Price, News & Analysis $24.90 -0.05 (-0.20%) (As of 07/5/2024 08:53 PM ET) Add Compare Share Share Today's Range$24.70▼$25.2050-Day Range$19.22▼$25.4752-Week Range$13.82▼$25.95Volume598,200 shsAverage Volume705,785 shsMarket Capitalization$2.25 billionP/E RatioN/ADividend YieldN/APrice Target$25.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Myriad Genetics alerts: Email Address Myriad Genetics MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside1.7% Upside$25.33 Price TargetShort InterestBearish6.73% of Shares Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.78Based on 5 Articles This WeekInsider TradingSelling Shares$3.57 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.36) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.00 out of 5 starsMedical Sector295th out of 879 stocksDiagnostic Substances Industry5th out of 12 stocks 2.2 Analyst's Opinion Consensus RatingMyriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 6 buy ratings, 2 hold ratings, and 2 sell ratings.Amount of Analyst CoverageMyriad Genetics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Myriad Genetics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.73% of the outstanding shares of Myriad Genetics have been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Myriad Genetics has recently increased by 26.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMyriad Genetics has received a 58.24% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools", "Computerized clinical decision support software", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Myriad Genetics is -0.60. Previous Next 2.7 News and Social Media Coverage News SentimentMyriad Genetics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Myriad Genetics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for MYGN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Myriad Genetics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,574,217.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Myriad Genetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Myriad Genetics are expected to grow in the coming year, from ($0.36) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -8.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -8.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Myriad Genetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Myriad Genetics Stock (NASDAQ:MYGN)Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Read More MYGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYGN Stock News HeadlinesJune 18, 2024 | marketbeat.comMyriad Genetics Sees Stock Surge with Hereditary Cancer TestsMyriad Genetics Inc. NASDAQ: MYGN is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including hereditary cancer tests that assess the risk for developing certain types of cancer based on genetics.June 18, 2024 | marketbeat.comMyriad Genetics Sees Stock Surge with Hereditary Cancer Tests (MYGN)Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests includingJuly 8, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.July 2, 2024 | gurufocus.comWhat's Driving Myriad Genetics Inc's Surprising 25% Stock Rally?July 2, 2024 | americanbankingnews.comMyriad Genetics, Inc. (NASDAQ:MYGN) Sees Large Growth in Short InterestJuly 2, 2024 | globenewswire.comMyriad Genetics Earns 2024 Great Place To Work® Certification™June 30, 2024 | americanbankingnews.comMyriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Rating of "Hold" by AnalystsJune 24, 2024 | globenewswire.comSurvey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the ElectionJuly 8, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.June 3, 2024 | globenewswire.comGenetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment ToolMay 30, 2024 | globenewswire.comQIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applicationsMay 23, 2024 | ca.finance.yahoo.comMYGN Aug 2024 33.000 callMay 23, 2024 | globenewswire.comMyriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual MeetingMay 23, 2024 | ca.finance.yahoo.comMYGN Jun 2024 22.000 putMay 16, 2024 | globenewswire.comNew Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate CancerMay 16, 2024 | finance.yahoo.comInsider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN)May 16, 2024 | finance.yahoo.comInsider Sale: President and CEO Paul Diaz Sells 227,844 Shares of Myriad Genetics Inc (MYGN)May 11, 2024 | finance.yahoo.comAnalysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter ReportSee More Headlines Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:MYGN CUSIP62855J10 CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,700Year Founded1991Price Target and Rating Average Stock Price Target$25.33 High Stock Price Target$35.00 Low Stock Price Target$14.00 Potential Upside/Downside+1.7%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-263,300,000.00 Net Margins-30.30% Pretax Margin-30.42% Return on Equity-6.77% Return on Assets-4.37% Debt Debt-to-Equity Ratio0.05 Current Ratio1.99 Quick Ratio1.82 Sales & Book Value Annual Sales$753.20 million Price / Sales2.99 Cash FlowN/A Price / Cash FlowN/A Book Value$9.53 per share Price / Book2.61Miscellaneous Outstanding Shares90,510,000Free Float88,607,000Market Cap$2.25 billion OptionableOptionable Beta1.95 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Paul J. Diaz (Age 62)CEO, President & Director Comp: $2.31MMr. Samraat S. Raha (Age 51)Chief Operating Officer Comp: $514.76kDr. Dale Muzzey Ph.D. (Age 44)Chief Scientific Officer Comp: $816.5kMr. Mark S. Verratti (Age 56)Chief Commercial Officer Comp: $915.81kMr. Scott J. Leffler (Age 49)Chief Financial Officer Ms. Natalie Munk (Age 43)Principal Accounting Officer Dr. Kevin Richard Haas Ph.D. (Age 38)Chief Technology Officer Comp: $580.36kMr. Matthew ScaloSenior Vice President of Investor RelationsMr. Glenn FarrellSenior VP & Chief Marketing OfficerMs. Shereen Solaiman (Age 51)Chief People Officer More ExecutivesKey CompetitorsIntellia TherapeuticsNASDAQ:NTLAQuidelOrthoNASDAQ:QDELMeridian BioscienceNASDAQ:VIVOHeskaNASDAQ:HSKANeogenNASDAQ:NEOGView All CompetitorsInsiders & InstitutionsDekaBank Deutsche GirozentraleBought 2,980 shares on 6/4/2024Ownership: 0.039%Daniel K SpiegelmanSold 3,788 sharesTotal: $83,487.52 ($22.04/share)Comerica BankSold 2,855 shares on 5/17/2024Ownership: 0.088%Tidal Investments LLCBought 28,432 shares on 5/17/2024Ownership: 0.031%California State Teachers Retirement SystemBought 2,564 shares on 5/16/2024Ownership: 0.098%View All Insider TransactionsView All Institutional Transactions MYGN Stock Analysis - Frequently Asked Questions How have MYGN shares performed this year? Myriad Genetics' stock was trading at $19.14 on January 1st, 2024. Since then, MYGN shares have increased by 30.1% and is now trading at $24.90. View the best growth stocks for 2024 here. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.09. The business's revenue for the quarter was up 11.6% on a year-over-year basis. What is Paul Diaz's approval rating as Myriad Genetics' CEO? 12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees. Does Myriad Genetics have any subsidiaries? The following companies are subsidiaries of Myriad Genetics: Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and more. How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY) and Puma Biotechnology (PBYI). This page (NASDAQ:MYGN) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free mygn Stock Alerts